Corcept Therapeutics (NASDAQ:CORT) Reaches New 1-Year High Following Earnings Beat

Corcept Therapeutics Incorporated (NASDAQ:CORT)’s stock price hit a new 52-week high during trading on Thursday after the company announced better than expected quarterly earnings. The company traded as high as $107.25 and last traded at $111.2780, with a volume of 53423 shares traded. The stock had previously closed at $92.95.

The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.34. The business had revenue of $256.15 million for the quarter, compared to analyst estimates of $221.15 million. Corcept Therapeutics had a net margin of 6.14% and a return on equity of 7.40%. Corcept Therapeutics’s revenue was up 31.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.29 earnings per share.

Corcept Therapeutics News Summary

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Quarterly results exceeded expectations. Corcept reported revenue of $256.1 million, up 31.7% year over year and well above the approximately $221 million consensus estimate. Adjusted earnings were $0.36 per share, surpassing expectations that ranged from a small loss to $0.02 per share and improving from $0.29 a year earlier. Operating profit rose 54.8% to $41.3 million. Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
• Positive Sentiment: Management raised its 2026 revenue outlook. Corcept now expects full-year revenue of approximately $1.1 billion to $1.2 billion, above the roughly $1.0 billion analyst consensus. Management cited continued momentum in its oncology and Cushing’s syndrome businesses. Corcept Therapeutics Shares Surge After Hours Following Q2 Results and Raised Guidance
• Positive Sentiment: The company maintained financial flexibility. Corcept ended the quarter with $111 million in cash and equivalents, generated $33.5 million in operating cash flow, and reported modest capital spending, supporting continued investment in its pipeline and commercial operations. Corcept Therapeutics Stock Rises on Q2 2026 Earnings
• Neutral Sentiment: Investor expectations are now elevated. CORT trades near its 52-week high, with a reported price-to-earnings ratio above 265. Recent analyst targets vary widely, from $72 to $135, indicating significant disagreement over the appropriate valuation.
• Negative Sentiment: Insider selling and a downgrade remain overhangs. Reported insider activity over the past six months shows substantially more selling than buying, while Wolfe Research downgraded the shares to Underperform. These signals may temper enthusiasm after the earnings-driven rally. Wolfe Research Downgrades Corcept Therapeutics to Underperform

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. Canaccord Genuity Group upped their target price on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Wednesday. HC Wainwright lifted their target price on shares of Corcept Therapeutics from $95.00 to $165.00 and gave the company a “buy” rating in a research note on Thursday. UBS Group set a $135.00 price target on Corcept Therapeutics in a research report on Thursday, May 28th. Zacks Research raised Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, May 4th. Finally, Wolfe Research cut Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 target price for the company. in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Corcept Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $106.33.

Insider Activity at Corcept Therapeutics

In related news, insider Sean Maduck sold 25,000 shares of Corcept Therapeutics stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $88.35, for a total value of $2,208,750.00. Following the sale, the insider owned 9,755 shares of the company’s stock, valued at approximately $861,854.25. This trade represents a 71.93% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David L. Mahoney sold 20,000 shares of the business’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $84.53, for a total transaction of $1,690,600.00. Following the sale, the director directly owned 26,147 shares in the company, valued at $2,210,205.91. This trade represents a 43.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 300,000 shares of company stock valued at $22,088,050 over the last three months. Insiders own 20.70% of the company’s stock.

Institutional Trading of Corcept Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CORT. Advisory Services Network LLC bought a new stake in Corcept Therapeutics during the third quarter worth about $25,000. Larson Financial Group LLC grew its stake in Corcept Therapeutics by 2,326.3% in the third quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 442 shares in the last quarter. Gould Capital LLC increased its position in shares of Corcept Therapeutics by 50.0% during the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 200 shares during the last quarter. Torren Management LLC acquired a new position in shares of Corcept Therapeutics during the 4th quarter worth approximately $25,000. Finally, CIBC Private Wealth Group LLC raised its stake in shares of Corcept Therapeutics by 128.5% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 770 shares of the biotechnology company’s stock worth $64,000 after purchasing an additional 433 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company’s stock.

Corcept Therapeutics Trading Up 26.1%

The company has a market cap of $12.59 billion, a P/E ratio of 332.58 and a beta of 0.47. The business has a 50 day moving average price of $82.51 and a 200-day moving average price of $55.80.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.